IL22 and Down syndrome: There was no correlation between the mRNA expression level of IL-22 and clinical characteristics such as age, duration of relapse, localization of relapse, EDSS at the time of relapse, Multiple Sclerosis Severity Score, lesion load on MRI assessed by the Barkhof criteria, presence or absence of spinal cord lesion on MRI, presence or absence of gadolinium enhancement on MRI, presence or absence of oligoclonal bands in the CSF, clinical status (Clinically isolated syndrome, patients fulfilling the 2010 McDonald criteria for MS or patients with clinically definite MS) and disease duration.